Standout Papers

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma... 2011 2026 2016 2021 1.0k
  1. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma (2016)
    Antonio Palumbo, Asher Chanan‐Khan et al. New England Journal of Medicine
  2. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (2011)
    Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 58 standout
Sub-graph 1 of 18

Citing Papers

The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
Systemic lupus erythematosus
2024 Standout
10 intermediate papers

Works of William Deraedt being referenced

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
2016 Standout
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
2012
and 4 more

Author Peers

Author Last Decade Papers Cites
William Deraedt 2187 1506 1670 53 2.6k
Jean‐Luc Harousseau 2558 1608 2181 42 3.3k
Klaus Hollmig 3131 1598 2673 48 3.6k
Lotfi Benboubker 2481 1686 2252 100 3.2k
Mauricio Pineda‐Roman 3224 1704 3011 57 4.0k
Martin Kropff 2472 1605 2035 67 3.0k
Meral Beksaç 2239 1295 1242 113 2.8k
Richard LeBlanc 2131 1463 2195 104 3.2k
Antonio Palumbo 3391 1963 2574 127 4.0k
RA Kyle 1478 748 1671 30 2.4k
PR Greipp 1549 778 1475 33 2.3k

All Works

Loading papers...

Rankless by CCL
2026